IRWD · Ironwood Pharmaceuticals
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $4.00
Note written ·
How this view changed
- · Rated Medium. Guidance, 5 November 2026: On 5 November 2026 Ironwood reported Q3 2026 adjusted EBITDA of $97.9 million and raised 2026 revenue guidance to $485–510 million and adjusted EBITDA guidance to above $350 million, which resolves the open question of whether the October share decline had an operating cause.
Price against the kill line
20.8% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $4.00, on record since 10 November 2026. The shares are up 10.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $4.00, under both the 50-day and 200-day moving averages, which would erase the rise that followed the 5 November 2026 report. A cut to 2026 guidance of $485–510 million revenue or adjusted EBITDA above $350 million would also show the case failing.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 133
- Revenue, change on a year (%)
- +9.0
- Operating margin (%)
- 70.0
- Net cash, cash less debt ($M)
- −239
- Price to earnings (×)
- 5.3
- Enterprise value to sales (×)
- 2.6
- Enterprise value to operating income (×)
- 4.1
All filed numbers
What Ironwood Pharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 133 | +9.0 | 70.0 |
| first filed | 113 | +32.6 | 70.2 |
| first filed | 107 | +158.9 | 68.1 |
| first filed | 47.7 | −47.3 | 14.3 |
| first filed | 122 | +33.3 | 61.8 |
| first filed | 85.2 | −9.7 | 53.2 |
| Pre-tax income ($M) | 87.6 |
| Net income ($M) four quarters: 150 | 59.8 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −5.4 |
| Operating cash flow ($M) | 205 |
| Capital spending ($M) four quarters to 30 September 2025, filed 5 November 2026 | 0.0 |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 86.4 |
| Debt ($M) credit line | 325 |
| Net cash, cash less debt ($M) | −239 |
| Deferred revenue ($M) +20.4% on a year | 1.3 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 133 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | −97.2 |
| Market value ($M) | 800 |
| Enterprise value, market value plus net debt ($M) | 1,038 |
| Enterprise value to sales (×) | 2.6 |
| Enterprise value to operating income (×) | 4.1 |
| Price to earnings (×) | 5.3 |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 9.6% of shares outstanding sold short, 8.0 days of average trading to cover, +2.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $22.6M |
The thesis
Ironwood Pharmaceuticals is modestly more likely to beat the S&P 500 over the next three months. It raised 2026 guidance for the second straight quarter on 5 November 2026 and is paying down debt. What settles the call is 2027: management said no further pricing tailwinds are expected in 2027 and 2028, declined to give 2027 guidance, and faces a Medicare price cut on 1 January 2027.
Third-quarter 2026 total revenue was $133.0 million against $122.1 million a year earlier. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was a record $97.9 million (Ironwood results release, 5 November 2026). Guidance now stands at $485–510 million of revenue and adjusted EBITDA above $350 million, up from $460–485 million and above $310 million in August.
The shares closed at $4.03 on 5 November 2026 and $4.85 on 12 November 2026, and the 3-month change is 12.5% (adjusted daily closes). Most of the market's response to the report is already in the price. The rating is Medium because the operating results are improving while the 2027 price cut is known and unpriced in guidance.
Bullish and bearish views on Ironwood Pharmaceuticals, Inc.
The bull case on Ironwood Pharmaceuticals, Inc. (IRWD), in brief: profit guidance keeps rising. The bear case: net price is falling.
Bull case
- Profit guidance keeps rising. Adjusted EBITDA guidance moved from above $310 million to above $350 million on 5 November 2026. Third-quarter commercial margin on LINZESS was 79.8% versus 75.9% a year earlier.
- Earnings beat estimates. Adjusted earnings per share were $0.36 against a $0.30 consensus at Zacks and Earnings Whispers (5 November 2026). GAAP net income was $59.8 million.
- Prescription demand is growing. LINZESS prescriptions rose 4.9% from a year earlier in the third quarter, per IQVIA as cited by Zacks. U.S. net sales were $324.9 million, up 3.2%.
- Debt keeps falling. The revolving credit facility stood at $325.0 million after a $60.0 million repayment in the third quarter, and no convertible notes remained at 30 September 2026 (Ironwood release). Management's year-end target is gross debt below $300 million.
- Costs are falling. Total costs were $39.9 million versus $46.6 million a year earlier, and selling, general and administrative expense nearly halved to $11.6 million (Earnings Whispers, 5 November 2026).
Bear case
- Net price is falling. Net sales growth of 3.2% trailed demand growth of 4.9% because of unfavorable gross-to-net rebate reserves versus the 2025 quarter (Zacks, 5 November 2026). Earnings Whispers describes net price as declining at a low-single-digit rate.
- 2027 carries a known price cut. The Medicare Part D maximum fair price of $136 per month for LINZESS takes effect on 1 January 2027, and management declined to guide 2027 on the 5 November 2026 call.
- Revenue missed the consensus. Total revenue of $133.0 million compared with a $149 million consensus at Earnings Whispers and Zacks, even as profit beat.
- The low end of guidance implies a flat quarter. Earnings Whispers calculates fourth-quarter revenue of roughly $132–157 million under the new range, so the low end would only match the third quarter.
- Insider activity in 2026 has been selling. Director Alexander Denner sold 6,730,800 shares at $3.05 on 17 March 2026, and CFO Ronald Silver sold 127,890 shares at $4.52 on 7 July 2026 (SEC Form 4). A Form 4 filed 17 September 2026 shows a grant of 3,694 shares to Denner on 15 September 2026.
- Apraglutide is a cost before it is a catalyst. Research and development expense was $28.3 million in the third quarter (Earnings Whispers). The STARS-2 trial is activating more than 100 sites, and management cited a 2029 regulatory filing, subject to results.
Price setup
The shares closed at $4.85 on 12 November 2026. That is 16.1% below the 52-week intraday high of $5.78 on 2 January 2026 and well above the 52-week closing low of $3.04 on 20 March 2026.
The climb after the report was quick: closes of $4.03 on 5 November 2026, $4.39 on 6 November 2026, $4.68 on 9 November 2026 and $4.81 on 10 November 2026. Closes since then have held in a narrow band, $4.87 on 11 November 2026 and $4.85 on 12 November 2026. The 50-day moving average is $3.96 and the 200-day moving average is $3.95, both as of 12 November 2026, so the shares now trade about 22% above both.
Before the report, the adjusted close slid from $4.36 on 18 September 2026 to $3.51 on 27 October 2026, with no filing reporting weaker sales. That decline has now been reversed.
Coverage is thin, with four analysts in the S&P Global poll. No Form 4 filing shows an insider purchase this year.
Catalysts ahead
- 31 December 2026: Management target of gross debt below $300 million by year end. The revolver stood at $325.0 million on 30 September 2026, so the target needs further repayment from fourth-quarter cash flow.
- 1 January 2027: Medicare Part D maximum fair price of $136 per month for LINZESS takes effect; Tammi Gaskins becomes CEO. This is the main 2027 pricing risk management has identified and the first day of the new CEO's tenure.
- ~5 January 2027 (est.): Initial 2027 guidance. Management declined to guide 2027 on 5 November 2026; the figures show whether LINZESS sales hold near the 2026 range once pricing tailwinds end.
What would change the view
A daily close below $4.00, under both the 50-day and 200-day moving averages, which would erase the rise that followed the 5 November 2026 report. A cut to 2026 guidance of $485–510 million revenue or adjusted EBITDA above $350 million would also show the case failing.
The risks this note tracks, each with what would confirm it:
- The 2027 Medicare price cut and the end of rebate tailwinds push LINZESS net sales below the 2026 range. Confirmed by: initial 2027 guidance, expected around 5 January 2027, puts LINZESS U.S. net sales below the 2026 guide of $1.20–1.25 billion.
- Net price keeps eroding faster than prescription demand grows. Confirmed by: fourth-quarter LINZESS net sales growth stays below the 4.9% prescription demand growth reported for the third quarter, or gross-to-net rebate reserves rise again.
- Apraglutide spending absorbs the guided profit. Confirmed by: quarterly research and development expense, $28.3 million in the third quarter of 2026 per Earnings Whispers, rises materially as STARS-2 activates more than 100 sites.
- The strategic review ends without a transaction. Confirmed by: a company statement that the review has concluded, or continued silence through the next quarterly report.
What it trades with
Ironwood's revenue depends on one drug sold by AbbVie, which records U.S. LINZESS net sales, so AbbVie's reported LINZESS sales and Medicare pricing policy matter more to the shares than the biotech sector does. The shares have moved on company-specific news in 2026: guidance raises in August and November, and the autumn slide with no sales warning. A takeover outcome from the Goldman-run strategic review, open since April 2025 with no announced bidder, would break any link to sector moves.
The evidence, claim by claim (7)
- Third-quarter 2026 total revenue was $133.0 million versus $122.1 million a year earlier; GAAP net income was $59.8 million ($0.36 per diluted share); adjusted EBITDA was a record $97.9 million. Ironwood third-quarter 2026 results release (8-K exhibit 99.1) · as of
- 2026 guidance raised to U.S. LINZESS net sales of $1.20–1.25 billion, total revenue of $485–510 million and adjusted EBITDA above $350 million (prior: $1.15–1.20 billion, $460–485 million, above $310 million). Ironwood third-quarter 2026 results release (8-K exhibit 99.1) · as of
- U.S. LINZESS net sales were $324.9 million, up 3.2% from a year earlier, while prescription demand grew 4.9% per IQVIA; commercial margin was 79.8% versus 75.9%. Ironwood third-quarter 2026 results release; Zacks summary · as of
- Revolving credit facility outstanding was $325.0 million after a $60.0 million third-quarter repayment; cash was $86.4 million; no convertible notes remained. Ironwood third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Management sees no further pricing tailwinds in 2027 and 2028, declined to give 2027 guidance, and the Medicare Part D maximum fair price of $136 per month for LINZESS takes effect 1 January 2027. Earnings Whispers review of the third-quarter 2026 call · as of
- Third-quarter adjusted EPS was $0.36 against a $0.30 consensus; revenue of $133.0 million missed a consensus of about $149 million. Earnings Whispers; Zacks · as of
- The adjusted close rose from $4.03 on 5 November 2026 to $4.85 on 12 November 2026; the 50-day moving average was $3.96 and the 200-day moving average $3.95. Split-adjusted daily closes · as of
Sources